Literature DB >> 9500522

Interleukin-5 binds to heparin/heparan sulfate. A model for an interaction with extracellular matrix.

R J Lipscombe1, A M Nakhoul, C J Sanderson, D R Coombe.   

Abstract

Interleukin-5 (IL-5) is the major cytokine regulating eosinophil production. In allergic disease tissue damage is primarily caused by eosinophils. Heparan sulfate proteoglycans are components of the bone marrow stroma, which supports hemopoietic cell differentiation and proliferation. We show that at low IL-5 concentrations heparan sulfate enhances the proliferation of an IL-5-dependent cell line. To investigate a mechanism for this effect we used an artificial proteoglycan to establish an enzyme-linked immunosorbent assay for the binding of heparin to proteins. Using this assay we demonstrate that IL-5 binds to heparin. The IL-5/heparin interaction is inhibited by ethylenediaminetetraacetate and enhanced by low concentrations of zinc ions. IL-5 interacts with iduronic acid containing glycosaminoglycans, and heparan sulfate preparations that have numerous N-sulfated domains per chain are especially efficient at inhibiting heparin binding. Both IL-5/heparin binding and the synergistic effect of IL-5 and heparan sulfate on cell proliferation were inhibited by an anti-IL-5 monoclonal antibody. These data suggest that the binding of IL-5 to heparan sulfate modulates IL-5 activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9500522     DOI: 10.1002/jlb.63.3.342

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  15 in total

Review 1.  Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infection.

Authors:  Sean Gill; Thomas N Wight; Charles W Frevert
Journal:  Anat Rec (Hoboken)       Date:  2010-06       Impact factor: 2.064

2.  Amino acid residues involved in the heparin-binding activity of murine IL-12 in the context of an antibody-cytokine fusion protein.

Authors:  Rosendo Luria-Pérez; Pierre V Candelaria; Tracy R Daniels-Wells; José A Rodríguez; Gustavo Helguera; Manuel L Penichet
Journal:  Cytokine       Date:  2019-05-20       Impact factor: 3.861

Review 3.  Proteoglycans as Immunomodulators of the Innate Immune Response to Lung Infection.

Authors:  Inkyung Kang; Mary Y Chang; Thomas N Wight; Charles W Frevert
Journal:  J Histochem Cytochem       Date:  2018-01-12       Impact factor: 2.479

4.  Helicobacter pylori and toll-like receptor agonists induce syndecan-4 expression in an NF-kappaB-dependent manner.

Authors:  Michael F Smith; Jennifer Novotny; Virginia S Carl; Laurey D Comeau
Journal:  Glycobiology       Date:  2005-11-29       Impact factor: 4.313

Review 5.  Defining the versican interactome in lung health and disease.

Authors:  Fengying Tang; Jourdan E Brune; Mary Y Chang; Stephen R Reeves; William A Altemeier; Charles W Frevert
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-01       Impact factor: 5.282

6.  Deficiency of endothelial heparan sulfates attenuates allergic airway inflammation.

Authors:  Riaz I Zuberi; Xiao Na Ge; Shuxia Jiang; Nooshin S Bahaie; Bit Na Kang; Reza M Hosseinkhani; Elizabeth M Frenzel; Mark M Fuster; Jeffrey D Esko; Savita P Rao; P Sriramarao
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

7.  Paradigms of sulfotransferase catalysis: the mechanism of SULT2A1.

Authors:  Ting Wang; Ian Cook; Charles N Falany; Thomas S Leyh
Journal:  J Biol Chem       Date:  2014-07-23       Impact factor: 5.157

Review 8.  The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance.

Authors:  Eleni Papakonstantinou; George Karakiulakis
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

9.  Benzylpenicillin differentially conjugates to IFN-gamma, TNF-alpha, IL-1beta, IL-4 and IL-13 but selectively reduces IFN-gamma activity.

Authors:  B M Brooks; A L Thomas; J W Coleman
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

Review 10.  Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease.

Authors:  Alba B Souza-Fernandes; Paolo Pelosi; Patricia R M Rocco
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.